Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

CD34, RAB20, PU.1 and GFI1 mRNA expression in myelodysplastic syndrome.

Authors: Huh, HJ  Chae, SL  Lee, M  Hong, KS  Mun, YC  Seong, CM  Chung, WS  Huh, JW 
Citation: Huh HJ, etal., Int J Lab Hematol. 2009 Jun;31(3):344-51. doi: 10.1111/j.1751-553X.2008.01056.x. Epub 2008 Mar 25.
Pubmed: (View Article at PubMed) PMID:18371060
DOI: Full-text: DOI:10.1111/j.1751-553X.2008.01056.x

Myelodysplastic syndrome (MDS) with hypocellular bone marrow (BM) is often difficult to distinguish from aplastic anemia (AA). Furthermore, the diagnosis of MDS with low blast counts and normal karyotype may be problematic. These issues highlight the need for a reliable marker for the diagnosis of MDS. This study was conducted to determine if changes of mRNA expression in any of the four selected genes would be useful markers for differentiation of hypoplastic MDS from AA, and MDS from benign disease, as well as to investigate whether mRNA expressions differ between MDS risk subgroups. Thirty-five patients diagnosed with MDS, 27 patients with AA and 17 patients with benign diseases were included. The CD34, RAB20, PU.1 and GFI1 mRNA levels were measured by real-time RT-PCR. The CD34 mRNA expressions in hypoplastic MDS were higher than those found in AA. PU.1 and GFI1 mRNA expressions were significantly lower in MDS with low blast counts and normal karyotype than those of benign disease. High-risk MDS showed higher CD34 expressions than those of low-risk MDS. This study suggests that measurement of CD34 and GFI1 mRNA expressions could be useful as a diagnostic and prognostic marker for MDS.

Annotation

Disease Annotations
Objects Annotated

Additional Information

 
CRRD Object Information
CRRD ID: 11040459
Created: 2016-03-08
Species: All species
Last Modified: 2016-03-08
Status: ACTIVE



NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.